How many clinical trials are running for zanubrutinib?

ClinicalTrials.gov lists more than 16 phase 2–4 zanubrutinib trials. This page tracks the 16 largest by enrolment: 13 phase 2, 3 phase 3, and 0 phase 4 among them, with 6 actively recruiting. Updated daily.

Where does this data come from?

All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.

Can I compare zanubrutinib against other drugs?

Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Targeted & bispecific oncology · Live ClinicalTrials.gov data

Zanubrutinib (Brukinsa) clinical trial pipeline

The timeline below tracks the 16 largest phase 2–4 zanubrutinib trials on ClinicalTrials.gov by enrolment, 6 of them actively recruiting. The next phase 3 primary completion among them is expected Aug 2028. Refreshed daily — add up to four competitors to compare pipelines side by side.

16+

Major trials tracked

Phase 3 trials

Actively recruiting

Aug 2028

Next phase 3 primary completion

2,084

Participants across trials

BeiGene

Lead sponsor by trial count

zanubrutinib (16)13 active2017–2033

Hide completed

zanubrutinib

Key

Actual date

Anticipated

Forecast to primary completion

RecruitingActive, not recruitingNot yet recruitingCompletedUnknown status

'17

'19

'21

'23

'25

'27

'29

'31

'33

zanubrutinib

ASPENP3

Study of BTK Inhibitor BGB-3111 in Chinese Subjects With Relapsed/Refractory Waldenström's Macroglobulinemia (WM)P2

MAGNOLIAP2

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)P2

CLL-RT1P2

Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Rituximab or Zanubrutinib Alone) for Waldenstrom's Macroglobulinemia/Lymphoplasmacytic LymphomaP2

Zanubrutinib and Eltrombopag as Second-line Treatment in Adults With Primary Immune ThrombocytopeniaP2

Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based ObinutuzumabP2

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)P3

MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLLP2

The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-cell LymphomaP3

Epco, Zanu, Ritux for R/R FL or MZLP2

Benefit VAP2

ZBR in WMP2

ZR2 Versus R2 Regimen in the Treatment of Newly Diagnosed Follicular LymphomaP2

ZSP2

Upcoming readouts

12 ahead · zanubrutinib

Select a trial to load its full ClinicalTrials.gov record.

Key zanubrutinib trials

Top 12 of the 16 tracked phase 2–4 trials, ordered by phase and status. Each links to its full ClinicalTrials.gov record.

Trial	Title	Phase	Status	Primary completion
NCT06522555	The Efficacy and Safety of Pola-ZR2 Versus ZR2 in the Treatment of Old Patients With de Novo Diffuse Large B-c…	Phase 3	Recruiting	Aug 2028
NCT06073821	Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Pa…	Phase 3	Active, not recruiting	Feb 2032
NCT03053440	ASPEN — A Study Comparing BGB-3111 and Ibrutinib in Participants With Waldenström's Macroglobulinemia (WM)	Phase 3	Completed	Jun 2022
NCT04271956	CLL-RT1 — Efficacy and Safety of Zanubrutinib Plus Tislelizumab Treatment with or Without Sonrotoclax for Patients with …	Phase 2	Recruiting	Aug 2026
NCT03824483	Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Sma…	Phase 2	Recruiting	Feb 2027
NCT06563596	Epco, Zanu, Ritux for R/R FL or MZL	Phase 2	Recruiting	Mar 2028
NCT04840602	Testing the Combination of Venetoclax and Rituximab, in Comparison to the Usual Treatment (Ibrutinib Plus Ritu…	Phase 2	Recruiting	Mar 2028
NCT06520098	Benefit VA — A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Ch…	Phase 2	Recruiting	Jun 2030
NCT05650723	Zanubrutinib and Venetoclax as Initial Therapy for Chronic Lymphocytic Leukemia (CLL) With Response-based Obin…	Phase 2	Active, not recruiting	Mar 2027
NCT07259122	ZBR in WM — A Phase II Clinical Study of Zanubrutinib Combined With Four Cycles of CD20 Monoclonal Antibody and Reduced-Do…	Phase 2	Not yet recruiting	Jun 2028
NCT07682415	ZS — Zanubrutinib Induction Followed by Delayed Fixed-Duration Combination With Sonrotoclax for CLL/SLL：Stop Trial …	Phase 2	Not yet recruiting	Dec 2029
NCT06367374	MRD Guided Sonrotoclax and Zanubrutinib in Newly Diagnosed CLL/SLL	Phase 2	Not yet recruiting	Feb 2030

Compare zanubrutinib vs amivantamab Compare zanubrutinib vs tarlatamab

FAQ

How many clinical trials are running for zanubrutinib?: ClinicalTrials.gov lists more than 16 phase 2–4 zanubrutinib trials. This page tracks the 16 largest by enrolment: 13 phase 2, 3 phase 3, and 0 phase 4 among them, with 6 actively recruiting. Updated daily.
Where does this data come from?: All trial data is sourced from ClinicalTrials.gov (CTGov) and refreshed on this page daily.
Can I compare zanubrutinib against other drugs?: Yes. The free ComplyRx Trial Pipeline tool compares up to five drugs side by side on one timeline, with PNG and PDF export. Add any competitor in the search box above.

Join the waitlist

Be the first to access ComplyRx

We'll let you know as soon as your spot opens to use ComplyRx.

By joining, you agree to our Privacy Policy.

Upcoming readouts

Key zanubrutinib trials

Related drug pipelines

FAQ

Be the first to access ComplyRx